Pure Global AI
ChiCTR2100048439Not yet recruiting

Untitled Trial

A randomized, blinded, placebo controlled phase I clinical trial to evaluate the safety and tolerability of recombinant novel coronavirus (COVID 19) vaccine (CHO cells) in healthy people aged 3 to 17 years
Hu'nan Provincial Center for Disease Control and PreventionPhase 1Chinese Clinical Trial Registry
Study focus
Sponsor & location
Primary sponsor
Hu'nan Provincial Center for Disease Control and Prevention
Funder
Self funded
Location
China
Timeline & enrollment
Phase
Phase 1
Start date
N/A
End date
Dec 30, 2022
ICD-10 classifications
COVID-19, virus identifiedViral pneumonia, unspecifiedOther viral pneumoniaCOVID-19, virus not identifiedPneumonia in viral diseases classified elsewhere
Data source
Registry
Chinese Clinical Trial Registry
Trial ID
ChiCTR2100048439
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for ChiCTR2100048439 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hu'nan Provincial Center for Disease Control and Prevention and is currently Not yet recruiting. The study focuses on Novel Coronavirus Pneumonia (COVID 19).

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.